Antares Pharma Inc. (NASDAQ:ATRS) – Research analysts at Jefferies Group issued their Q1 2017 earnings per share (EPS) estimates for Antares Pharma in a research report issued to clients and investors on Friday. Jefferies Group analyst A. Petrone anticipates that the firm will earn ($0.04) per share for the quarter. Jefferies Group also issued estimates for Antares Pharma’s Q2 2017 earnings at ($0.03) EPS and Q3 2017 earnings at ($0.02) EPS.

Antares Pharma (NASDAQ:ATRS) last posted its quarterly earnings data on Wednesday, November 9th. The specialty pharmaceutical company reported ($0.04) EPS for the quarter, missing analysts’ consensus estimates of ($0.03) by $0.01. Antares Pharma had a negative return on equity of 45.93% and a negative net margin of 53.11%. The firm earned $13.50 million during the quarter, compared to analyst estimates of $11.15 million.

Earnings History and Estimates for Antares Pharma (NASDAQ:ATRS)

Other analysts have also issued research reports about the stock. Zacks Investment Research raised shares of Antares Pharma from a “hold” rating to a “buy” rating and set a $1.25 price objective on the stock in a research report on Friday, August 12th. Piper Jaffray Cos. reissued an “overweight” rating and issued a $2.00 price objective (down previously from $3.00) on shares of Antares Pharma in a research report on Saturday, August 13th.

Antares Pharma (NASDAQ:ATRS) opened at 1.87 on Monday. The firm’s market cap is $289.96 million. Antares Pharma has a 1-year low of $0.67 and a 1-year high of $1.95. The company has a 50-day moving average of $1.72 and a 200-day moving average of $1.26.

Hedge funds have recently bought and sold shares of the company. Fuller & Thaler Asset Management Inc. purchased a new stake in Antares Pharma during the second quarter valued at about $797,000. Perkins Capital Management Inc. purchased a new stake in Antares Pharma during the third quarter valued at about $1,020,000. Paloma Partners Management Co purchased a new stake in Antares Pharma during the second quarter valued at about $607,000. Courage Capital Management LLC raised its stake in Antares Pharma by 107.7% in the third quarter. Courage Capital Management LLC now owns 934,462 shares of the specialty pharmaceutical company’s stock valued at $1,570,000 after buying an additional 484,462 shares during the period. Finally, Laurion Capital Management LP purchased a new stake in Antares Pharma during the second quarter valued at about $467,000. 36.54% of the stock is currently owned by hedge funds and other institutional investors.

About Antares Pharma

Antares Pharma, Inc (Antares) is a specialty pharmaceutical company that focuses on developing and commercializing self-administered parenteral pharmaceutical products and technologies. The Company develops and manufactures pressure-assisted injector devices, with and without needles, which allow patients to self-inject drugs.

5 Day Chart for NASDAQ:ATRS

Receive News & Stock Ratings for Antares Pharma Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Antares Pharma Inc. and related stocks with our FREE daily email newsletter.